<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652259</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-9003-101</org_study_id>
    <secondary_id>IRB17-00253</secondary_id>
    <nct_id>NCT03652259</nct_id>
  </id_info>
  <brief_title>Gene Delivery Clinical Trial of SRP-9003 for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)</brief_title>
  <official_title>A Single-Center, Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 Administered by Systemic Infusion in Subjects With LGMD2E (β-Sarcoglycan Deficiency)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed clinical trial is the first-in-human, single-center, open-label, gene delivery&#xD;
      study of SRP-9003 in participants with LGMD2E.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Anticipated">February 14, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of Beta-Sarcoglycan (β-SG) Protein Expression at Day 60, as Measured by Western Blot</measure>
    <time_frame>Baseline, Day 60</time_frame>
    <description>β-SG gene expression levels will be quantified by Western Blot and compared between pre and post muscle biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of β-SG Protein Expression at Day 60, as Measured by Immunofluorescence</measure>
    <time_frame>Baseline, Day 60</time_frame>
    <description>β-SG gene expression levels will be quantified by immunofluorescence and compared between pre and post muscle biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of β-SG Protein Expression at Day 60, as Measured by Immunohistochemistry Percent B-SG Positive Fibers</measure>
    <time_frame>Baseline, Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Limb-Girdle Muscular Dystrophy, Type 2E</condition>
  <arm_group>
    <arm_group_label>Cohort 1: SRP-9003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: SRP-9003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SRP-9003</intervention_name>
    <description>SRP-9003 will be administered through a single systemic injection.</description>
    <arm_group_label>Cohort 1: SRP-9003</arm_group_label>
    <arm_group_label>Cohort 2: SRP-9003</arm_group_label>
    <other_name>LGMD2E vector</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Males or females of any ethnic group&#xD;
&#xD;
          -  β-SG deoxyribonucleic acid (DNA) gene mutations at both alleles&#xD;
&#xD;
          -  Weakness demonstrated based on history of difficulty in running, jumping and climbing&#xD;
             stairs&#xD;
&#xD;
          -  A 100 meter walk/run (MWR) test result: ≥40 % of predicted for age-, height-, gender-,&#xD;
             and weight-matched healthy controls at the screening visit&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Active viral infection based on clinical observations&#xD;
&#xD;
          -  Cardiac magnetic resonance imaging (MRI) determined left ventricular ejection fraction&#xD;
             (LVEF) &lt;40%&#xD;
&#xD;
          -  Serological evidence of human immunodeficiency virus (HIV), hepatitis B, or hepatitis&#xD;
             C infection&#xD;
&#xD;
          -  Diagnosis of (or ongoing treatment for) an autoimmune disease&#xD;
&#xD;
          -  Abnormal laboratory values considered clinically significant&#xD;
&#xD;
          -  Concomitant illness or requirement for chronic drug treatment that, in the opinion of&#xD;
             the Principal Investigator, creates unnecessary risks for gene transfer.&#xD;
&#xD;
        Other inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>limb girdle muscular dystrophy</keyword>
  <keyword>LGMD2E</keyword>
  <keyword>beta-sarcoglycan</keyword>
  <keyword>gene transfer</keyword>
  <keyword>adeno-associated virus</keyword>
  <keyword>LGMDR4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
    <mesh_term>Sarcoglycanopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

